The expression of atrogin-1, MuRF-1, myostatin, and p-STAT3 was significantly reduced by the 2-DG treatment (Figure 3C) and prevented the transcriptional activation of MuRF-1 and atrogin-1, which was markedly increased in the cachexia group (Figure 3D). The gene discussed is STAT3; the disease is Cachexia.